

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD  
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

April 17, 2019

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

**AGENDA**

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for January 16, 2019 meeting
- IV. Secretary's report
- V. Old Business
  - Proposed protocol for dupilumab (Dupixent®).
  - Input from dermatologists, Dr. Linda S. Marcus and Dr. Booth Durham (DSNJ)
- VI. New Business
  - A. Proposed protocol for calcitonin gene-related peptide (CGRP) inhibitors
  - B. Proposed protocol for gout products
- VII. Newsletter on medication assisted treatment (MAT) products
- VIII. Informational Highlight/Reports
  - A. Report on major changes in top drugs ranking for April 2019 meeting
  - B. Informational Highlights/Reports
    - 1. DXC Technology/NJ HMO 4<sup>th</sup> Quarter 2018 Prior Authorization Report
    - 2. Summary of DURB Action Items
    - 3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)  
(b) Physician-administered/Antiviral drugs by amount paid
    - 4. Medication information:
      - (a) FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan
      - (b) Non-vitamin K oral anticoagulants (NOACs) Now Recommended Over Warfarin to Prevent A-Fib-related Stroke
      - (c) Benzodiazepine use may increase pneumonia risk
      - (d) Acetaminophen undetectable in more than half of related drug-induced liver injury (DILI)
      - (e) FDA warns of Higher Risk for Death With Gout Drug Febuxostat (Uloric)
      - (f) Hep C Infection May Be on the Rise Among Men Using PrEP
- IX. Referenced Material
  - A. Proposed protocol for dupilumab (Dupixent®)